Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis.
The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | 0.91 Increased by +2.25% | 0.83 Increased by +9.60% |
| Nov 6, 24 | 0.79 Increased by +9.72% | 0.70 Increased by +12.86% |
| Jul 30, 24 | 0.89 Increased by +14.10% | 0.70 Increased by +27.14% |
| May 7, 24 | 0.62 Increased by +16.98% | 0.62 |
| Feb 29, 24 | 0.89 Increased by +11.25% | 0.88 Increased by +1.14% |
| Nov 2, 23 | 0.72 Increased by +12.50% | 0.78 Decreased by -7.69% |
| Aug 2, 23 | 0.78 Increased by +52.94% | 0.76 Increased by +2.63% |
| May 3, 23 | 0.53 Decreased by -17.19% | 0.62 Decreased by -14.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 187.25 M Increased by +3.32% | 16.04 M Decreased by -35.50% | Increased by +8.57% Decreased by -37.57% |
| Sep 30, 24 | 168.57 M Increased by +2.83% | -143.47 M Decreased by -1.42 K% | Decreased by -85.11% Decreased by -1.38 K% |
| Jun 30, 24 | 178.02 M Increased by +5.05% | 18.89 M Decreased by -26.69% | Increased by +10.61% Decreased by -30.22% |
| Mar 31, 24 | 167.12 M Increased by +4.23% | 8.98 M Increased by +145.96% | Increased by +5.37% Increased by +144.10% |
| Dec 31, 23 | 181.24 M Increased by +5.40% | 24.87 M Increased by +346.19% | Increased by +13.72% Increased by +333.57% |
| Sep 30, 23 | 163.93 M Decreased by -2.11% | 10.86 M Increased by +1.67 K% | Increased by +6.62% Increased by +1.70 K% |
| Jun 30, 23 | 169.47 M Increased by +0.03% | 25.76 M Increased by +29.62% | Increased by +15.20% Increased by +29.58% |
| Mar 31, 23 | 160.34 M Increased by +1.49% | -19.54 M Decreased by -386.12% | Decreased by -12.18% Decreased by -381.92% |